PHARMACEUTICAL 2020

Lifecore Biomedical INC DE
Rank 152 of 363



PHARMACEUTICAL 2020

Lifecore Biomedical INC DE
Rank 152 of 363

LANDEC

The relative strengths and weaknesses of Lifecore Biomedical INC DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lifecore Biomedical INC DE compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 89% points.The greatest weakness of Lifecore Biomedical INC DE is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 77% points.

The company's Economic Capital Ratio, given in the ranking table, is 270%, being 32% points above the market average of 238%.

Input Variable	Value in 1000 USD
Assets, Current	133,041
Cost of Goods Sold	476,556
Intangible Assets	76,742
Liabilities, Current	137,091
Liabilities, Non-Current	88,931
Other Assets	109,281
Other Compr. Net Income	-1,084
Other Expenses	8,748
Other Liabilities	22,925
Other Net Income	1,684
Other Revenues	557,559
Property and Equipment	200,027
Research and Development	11,466
Selling, General and Administrative Expense	62,062

Output Variable	Value in 1000 USD
Assets	519,091
Liabilities	248,947
Expenses	558,832
Revenues	557,559
Stockholders Equity	270,144
Net Income	411
Comprehensive Net Income	-131
BaseVar	943,598
ECR before LimitedLiability	153%
Economic Capital Ratio	270%